New study showing drug prolongs life for patients with ovarian cancer

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives in a meaningful way. However, a new research study shows tremendous promise for a drug called niraparib to extend life when all options have been exhausted.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Related Links:

Publication date: Available online 22 August 2019Source: Cancer CellAuthor(s): Salma Parvin, Ariel Ramirez-Labrada, Shlomzion Aumann, XiaoQing Lu, Natalia Weich, Gabriel Santiago, Elena M. Cortizas, Eden Sharabi, Yu Zhang, Isidro Sanchez-Garcia, Andrew J. Gentles, Evan Roberts, Daniel Bilbao-Cortes, Francisco Vega, Jennifer R. Chapman, Ramiro E. Verdun, Izidore S. LossosSummaryDeficiency in DNA double-strand break (DSB) repair mechanisms has been widely exploited for the treatment of different malignances, including homologous recombination (HR)-deficient breast and ovarian cancers. Here we demonstrate that diffuse large B...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: End-of-life chemotherapy for OC patients is a thorny problem. More studies and a multidisciplinary approach are needed to better treat these patients. PMID: 31437848 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
Condition:   Epithelial Ovarian Cancer Intervention:   Drug: adjuvant chemotherapy Sponsors:   Japanese Gynecologic Oncology Group;   Korean Gynecologic Oncology Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Epithelial Ovarian Cancer Intervention:   Drug: adjuvant chemotherapy Sponsors:   Japanese Gynecologic Oncology Group;   Korean Gynecologic Oncology Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Epithelial Ovarian Cancer Intervention:   Drug: adjuvant chemotherapy Sponsors:   Japanese Gynecologic Oncology Group;   Korean Gynecologic Oncology Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionOur research suggests the experimental evidence for DFO and CDDP as a new effective combination therapy to enhance the efficacy of chemical therapy in ovarian cancer.
Source: Journal of Trace Elements in Medicine and Biology - Category: Biochemistry Source Type: research
CONCLUSIONS: Although CD146 immunoreactivity in tumor cells did not correlate with the routinely used clinico-pathological parameters, expression of CD146 in tumor cells was an independent pronostic factor for survival in serous ovarian carcinomas. Moreover, CD146 might be regarded as a novel biomarker of tumor neovasculature. PMID: 31424655 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
CONCLUSIONS: Despite the higher costs, NACT did not prove to be a more effective therapeutic strategy in terms of survival of patients with stage IIIC/IV ovarian cancer. Altogether, our results state that NACT might be less cost-effective than PDS. PMID: 31424651 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
ConclusionsOur data suggested that miR-1307 may be involved in the resistance of ovarian cancer to chemotherapy drugs via regulation of CIC, and should be further explored as a potential therapeutic target.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Ovarian Cancer | Ovaries | Pharmaceuticals | Study | Women